Contact for Regulatory or Compliance Questions If you have questions about regulatory status, compliance, or the appropriateness of this product for your setting, contact: Phone: +1 (888) 687-4334 Email: [email protected] This disclaimer was last updated in accordance with FDA and USP standards
Careful consideration of individual peptide mechanisms is crucial for designing effective and safe stacks
Convenience and Ease of Use Ready-to-Use: Pre-filled syringes come ready to use, eliminating the need for patients or healthcare providers to measure and draw the medication from a vial
Olmos, Brenda
Trial SURMOUNT-1 Trial Phase 3 multicenter, double-blind, randomized, placebo-controlled trial was conducted at 119 sites in nine countries Intervention Participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention